Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission.
Dulucq S, Hayette S, Cayuela JM, Bauduer F, Chabane K, Chevallier P, Cony-Makhoul P, Flandrin-Gresta P, Jeune CL, Bris YL, Legros L, Maisonneuve H, Roy L, Mahon FX, Sloma I, Rea D, Nicolini FE. Dulucq S, et al. Among authors: flandrin gresta p. Haematologica. 2022 Dec 1;107(12):2944-2949. doi: 10.3324/haematol.2022.280740. Haematologica. 2022. PMID: 35924576 Free PMC article. No abstract available.
Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib.
Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S, Janel A, Hayette S, Cohny-Makhoul P, Cadoux N, Cayuela JM, Campos L, Guyotat D, Flandrin-Gresta P. Genthon A, et al. Among authors: flandrin gresta p. Oncotarget. 2020 Jun 30;11(26):2560-2570. doi: 10.18632/oncotarget.27652. eCollection 2020 Jun 30. Oncotarget. 2020. PMID: 32655840 Free PMC article.
Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French Experience.
Alary AS, Maute C, Kosmider O, Sujobert P, Gauthier A, Macintyre E, Preudhomme C, Hayette S, Luque-Paz D, Baran-Marszak F, Davi F, Lippert E, Cornillet-Lefebvre P, Delfau-Larue MH, Cassinat B, Cayuela JM, Flandrin-Gresta P. Alary AS, et al. Among authors: flandrin gresta p. Hemasphere. 2021 Nov 17;5(12):e658. doi: 10.1097/HS9.0000000000000658. eCollection 2021 Dec. Hemasphere. 2021. PMID: 34805765 Free PMC article.
Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.
Fournier E, Heiblig M, Lespinasse C, Flandrin-Gresta P, Geay A, Miguet L, Fenwarth L, Vallat L, Soubeyrand B, Marceau-Renaut A, Plesa A, Preudhomme C, Sujobert P, Hayette S, Duployez N, Huet S. Fournier E, et al. Among authors: flandrin gresta p. Leukemia. 2022 May;36(5):1390-1400. doi: 10.1038/s41375-022-01534-z. Epub 2022 Mar 7. Leukemia. 2022. PMID: 35256762 No abstract available.
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).
Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F. Mohamed AM, et al. Oncotarget. 2016 Jan 19;7(3):2889-909. doi: 10.18632/oncotarget.3898. Oncotarget. 2016. PMID: 26284582 Free PMC article.
TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E. Mohamed AM, et al. Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16. Leuk Res. 2017. PMID: 28167452
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E. Solly F, et al. Clin Cancer Res. 2017 Jun 15;23(12):3025-3034. doi: 10.1158/1078-0432.CCR-16-2304. Epub 2016 Nov 23. Clin Cancer Res. 2017. PMID: 27881579
Expression of embryonic stem cell markers in acute myeloid leukemia.
Picot T, Aanei CM, Fayard A, Flandrin-Gresta P, Tondeur S, Gouttenoire M, Tavernier-Tardy E, Wattel E, Guyotat D, Campos L. Picot T, et al. Tumour Biol. 2017 Jul;39(7):1010428317716629. doi: 10.1177/1010428317716629. Tumour Biol. 2017. PMID: 28718379 Free article.
26 results